Department of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Digestive Diseases Center, Showa University, Koto-Toyosu Hospital, Koto-Ku, Tokyo, Japan.
Gastrointest Endosc. 2018 Apr;87(4):956-961. doi: 10.1016/j.gie.2017.02.007. Epub 2017 Feb 21.
Per-oral endoscopic myotomy (POEM) for achalasia is particularly appealing in the elderly because it is minimally invasive. However, data in patients aged ≥80 years are scarce. The aim of this study was to assess the clinical outcome of POEM in octogenarians.
This was a multicenter retrospective study at 8 centers. Consecutive octogenarians with achalasia who underwent POEM between 2010 and 2016 were included. Rates of technical success (completion of myotomy), clinical response (Eckardt score ≤3), and adverse events (severity graded as per American Society for Gastrointestinal Endoscopy lexicon) were assessed.
A total of 76 patients (47.4% female, mean age 84 years) underwent POEM for treatment of achalasia: type I, 17.1%; type II, 35.5%; type III, 17.1%; and unspecified, 30.3%. Overall, 41.1% were treatment naïve, whereas others had previous botulinum toxin injection and/or pneumatic dilation. The mean (± standard deviation [SD]) age-adjusted Charlson comorbidity index score was 6.2 ± 2.4, with the majority of patients having American Society of Anesthesiologists Physical Status Classification System (ASA) scores of II/III. Technical success was 93.4%, with a median follow-up of 256 days. Fourteen adverse events occurred in 11 patients (14.5%). There were 3 inadvertent mucosotomies, 6 cases of symptomatic capnoperitoneum and/or capnomediastinum, 2 esophageal leaks, 1 cardiac arrhythmia, and 2 other). The severities of these adverse events were mild (78.6%), moderate (14.3%), and severe (7.1%). Clinical success was achieved in 90.8% of patients, with a mean (± SD) Eckardt score reduction from 7.0 ± 2.3 to 0.8 ± 0.1 (P < .001), a median follow-up of 256 days, and interquartile range of 66 to 547.
Although the rate of technical success may be somewhat lower and the rate of adverse events slightly higher than previously reported, our data suggest that POEM in octogenarians is safe and effective, supporting its role as a primary modality for achalasia in this patient population.
经口内镜下肌切开术(POEM)治疗贲门失弛缓症在老年人中尤其具有吸引力,因为它是微创的。然而,目前关于 80 岁以上患者的数据较少。本研究旨在评估 POEM 在 80 岁以上人群中的临床效果。
这是在 8 个中心进行的多中心回顾性研究。纳入了 2010 年至 2016 年间接受 POEM 治疗的贲门失弛缓症 80 岁以上连续患者。评估了技术成功率(肌切开术完成)、临床反应(Eckardt 评分≤3)和不良事件(根据美国胃肠内镜学会词汇表分级严重程度)。
共有 76 例(47.4%为女性,平均年龄 84 岁)接受 POEM 治疗贲门失弛缓症:I 型 17.1%;II 型 35.5%;III 型 17.1%;未特指类型 30.3%。总体而言,41.1%为初次治疗,而其他患者则接受过肉毒杆菌毒素注射和/或气囊扩张治疗。年龄调整后的 Charlson 合并症指数评分的平均值(±标准差[SD])为 6.2±2.4,大多数患者的美国麻醉医师协会身体状况分类系统(ASA)评分为 II/III。技术成功率为 93.4%,中位随访时间为 256 天。11 例患者发生 14 例不良事件(14.5%)。发生 3 例意外黏膜切开、6 例有症状的气腹和/或气胸、2 例食管漏、1 例心律失常和 2 例其他不良事件。这些不良事件的严重程度为轻度(78.6%)、中度(14.3%)和重度(7.1%)。90.8%的患者达到临床成功,Eckardt 评分从 7.0±2.3 降至 0.8±0.1(P<0.001),平均(±SD)随访时间为 256 天,中位数为 66-547 天。
尽管技术成功率可能略低,不良事件发生率略高,但我们的数据表明,POEM 治疗 80 岁以上患者是安全有效的,支持其作为该患者群体贲门失弛缓症的主要治疗方法。